Tech Company Financing Transactions
RevolKa Funding Round
On 5/20/2025, RevolKa raised $1.4 million in Series A funding from D3, TOHOKU University Venture Partners and DeepCore.
Transaction Overview
Company Name
Announced On
5/20/2025
Transaction Type
Venture Equity
Amount
$1,400,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to advance its drug discovery programs for rare diseases and support collaborative partnering efforts.
Company Information
Company Status
Private & Independent
Industry
Manufacturing
Mailing Address
2-26-9 Hongo, Bunkyo-ku
Tokyo, 113-0033
Japan
Tokyo, 113-0033
Japan
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
"RevolKa" is derived from the Latin word for evolution (evolutio) and the Ainu word for raise (reska). Our company logo takes inspiration from the developing fetus and represents that to raise (R of reska) nurtures evolution (e of evolution) with care.? We have evolved the protein selected by life as a functional molecule into a frontier that could not be reached in nature by using evolutionary molecular engineering that mimics evolution in vitro using artificial intelligence technology as a guide. We will grow it as a functional molecule required by various fields focusing on medicine.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Norio Hamamatsu
Chief Scientific Officer
Mitsuo Umetsu
Co-Founder
Shiro Kataoka
Co-Founder
Hikaru Nakazawa
Browse more venture capital transactions:
Prev: 5/20/2025: Potr venture capital transaction
Next: 5/20/2025: Vero Leasing venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC transactions on this site are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs